Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Poractant alfa - Chiesi/Karolinska Institute

Drug Profile

Poractant alfa - Chiesi/Karolinska Institute

Alternative Names: CHF 1534; Curasurf; Curosurf; Curosurf LISA; Curosurf+catheter CHF6440; LISA combination product

Latest Information Update: 20 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi; Karolinska Institute
  • Developer Chiesi; Dey Laboratories
  • Class Phospholipids; Pulmonary surfactants
  • Mechanism of Action Cell membrane permeability modulators; Surface active agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neonatal respiratory distress syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neonatal respiratory distress syndrome
  • Phase II SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 25 Sep 2023 Cheisi terminates a phase I trial for Neonatal respiratory distress syndrome (following deep hypothermic circulatory arrest) (In infants, In neonates) in USA (NCT04181255)
  • 22 Sep 2022 Chiesi terminates the phase III LISPAP trial in Neonatal respiratory distress syndrome in USA due to sponsor's decision (NCT02772081)
  • 28 Mar 2022 Chiesi terminates a phase-II trial as enrolment has been extended 2 years in SARS-COV-2 acute respiratory disease in Italy, USA and UK (Endotracheal) (NCT04502433) (EudraCT2020-002632-75)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top